Payment overview · 2025
General Payments
$115,413.39
167 reported records · 8 companies
Healthcare provider profile · identity verified
Larry H. Lambertson
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · FORT WAYNE, IN · NPI 1124019005
Verified facts
What the public records show
CMS Open Payments records show Larry H. Lambertson received $115,413.39 in general payments during 2025 across 167 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 99.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Auvelity, Caplyta, Cobenfy, Ingrezza, Lybalvi, Qelbree, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Lybalvi by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vivitrol by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Auvelity by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported COBENFY as an associated drug or biological on 92858 records involving 21456 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Cobenfy by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Caplyta by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Rexulti by this doctor in 2024.
Supernus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Qelbree as an associated drug or biological on 61278 records involving 18421 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Qelbree by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $114,234.13 | 99.0% | 116 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $437.70 | 0.4% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $377.61 | 0.3% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.67 | 0.1% | 19 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.15 | 0.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.53 | 0.1% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $39.17 | 0.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $14.43 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $74,106.00 | 35 |
| Consulting Fee | $27,305.00 | 10 |
| Travel and Lodging | $10,586.54 | 27 |
| Food and Beverage | $3,415.85 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $80,027.25 | 89 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $437.70 | 10 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $377.61 | 16 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $336.00 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $174.67 | 19 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.15 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $54.53 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $39.17 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 82 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| COBENFY cobenfy |
2025 | Cobenfy | 2024 | 44 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Qelbree qelbree |
2025 | Qelbree | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 163 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
163 | 22 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | COBENFY open payments reported associated product |
CMS Open Payments — General Payments 92858 supporting records · 21456 recipient NPIs · example record 1184377695 |
Cobenfy · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
106 | 16 |
| Supernus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | Qelbree open payments reported associated product |
CMS Open Payments — General Payments 61278 supporting records · 18421 recipient NPIs · example record 1244861775 |
Qelbree · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 506 | 59 |
| Clozapine | Clozapine | 349 | 12 |
| Sertraline Hcl | Sertraline Hcl | 281 | 33 |
| Olanzapine | Olanzapine | 261 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 249 | 25 |
| Oxcarbazepine | Oxcarbazepine | 241 | 18 |
| Buspirone Hcl | Buspirone Hcl | 228 | 31 |
| Bupropion Xl | Bupropion Hcl | 217 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 216 | 28 |
| Propranolol Hcl | Propranolol Hcl | 215 | 26 |
| Benztropine Mesylate | Benztropine Mesylate | 213 | 21 |
| Lamotrigine | Lamotrigine | 190 | 14 |
| Gabapentin | Gabapentin | 188 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 184 | 11 |
| Mirtazapine | Mirtazapine | 168 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 165 | 14 |
| Vraylar | Cariprazine Hcl | 163 | 22 |
| Aripiprazole | Aripiprazole | 157 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 16 |
| Donepezil Hcl | Donepezil Hcl | 142 | 11 |
| Invega Sustenna | Paliperidone Palmitate | 137 | 14 |
| Paliperidone Er | Paliperidone | 134 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 18 |
| Divalproex Sodium | Divalproex Sodium | 116 | suppressed |
| Rexulti | Brexpiprazole | 106 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 87 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 82 | 13 |
| Lybalvi | Olanzapine/Samidorphan Malate | 80 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 78 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 74 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 72 | 11 |
| Ingrezza | Valbenazine Tosylate | 71 | suppressed |
| Lorazepam | Lorazepam | 70 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 66 | suppressed |
| Abilify Maintena | Aripiprazole | 59 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 58 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 51 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 47 | suppressed |
| Risperidone | Risperidone | 47 | suppressed |
| Cobenfy | Xanomeline Tart/Trospium Chlor | 44 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Austedo | Deutetrabenazine | 38 | suppressed |
| Caplyta | Lumateperone Tosylate | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 31 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 25 | suppressed |
| Aristada | Aripiprazole Lauroxil | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Qelbree | Viloxazine Hcl | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Vivitrol | Naltrexone Microspheres | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Quviviq | Daridorexant Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Disulfiram | Disulfiram | 13 | suppressed |
| Fanapt | Iloperidone | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Perseris | Risperidone | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115,413.39 · 167 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, Auvelity, CAPLYTA, COBENFY, INGREZZA, LYBALVI, Qelbree, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error